Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 338 followers
Latest posts
Last updated about 3 hours ago
Foundation Medicine tallies FDA nod to pair its blood test with Pfizer’s prostate cancer combo
about 3 hours ago
Foundation Medicine tallied another nod from the FDA for one of its...
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
about 3 hours ago
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million...
ASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
about 4 hours ago
To Roche, a phase 3 flop in first-line breast cancer does not...
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
about 6 hours ago
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare...
ASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push
about 8 hours ago
Cardiff Oncology has shared updated results from its phase 2 colorectal cancer...
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
about 8 hours ago
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took...
MindMaze Therapeutics culls program, ends legacy ops from Relief merger to cut costs
about 9 hours ago
Digital therapeutics specialist MindMaze Therapeutics is selling off a pipeline program whilst...
ASCO: Celcuity dares to dream of becoming $10B company after breast cancer win over Piqray
about 9 hours ago
While Revolution Medicines dominated this year’s American Society of Clinical Oncology annual...
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
about 9 hours ago
The first-in-class EGFRxHER3 bispecific ADC that BMS paid $800 million for has...
Praxis pauses one of its seizure programs after phase 2 fail
about 11 hours ago
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen...
Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
about 11 hours ago
Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to...
ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data
about 12 hours ago
Takeda and Innovent's long-term follow-up data from an early study of their...